Cambium Bio Ltd
Research Cambium Bio Ltd (CMB) on Bullrun: market cap AUD 11.48M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCMB
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyAUD
- Market capAUD 11.48M
- Financial periodFY2025
- Net income-AUD 3.84M
- Free cash flow-AUD 5.25M
Valuation Snapshot
latest market cap is AUD 11.48M.
About Cambium Bio Ltd
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing indications. Cambium Bio Limited is headquartered in Bella Vista, Australia.
Frequently asked questions
What is Cambium Bio Ltd's market cap?
Cambium Bio Ltd's market capitalization is AUD 11.48M.
What does Cambium Bio Ltd do?
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease.